Document is current
Any future updates will be listed below
-
Authors
Msaouel, Pavlos https://orcid.org/0000-0001-6505-8308
Yu, Kai
Yuan, Ying
Chen, Jianfeng
Yan, Xinmiao
Karki, Menuka
Duan, Fei
Sheth, Rahul A. https://orcid.org/0000-0001-9615-8985
Rao, Priya
Sircar, Kanishka
Shah, Amishi Y. https://orcid.org/0000-0002-9007-0621
Zurita, Amado J. https://orcid.org/0000-0002-3805-7307
Genovese, Giannicola https://orcid.org/0000-0003-1392-9954
Li, Min
Yeh, Chih-Chen
Dang, Minghao https://orcid.org/0000-0001-7287-2877
Han, Guangchun https://orcid.org/0000-0001-9277-2507
Chu, Yanshuo
Hallin, Max
Olson, Peter
Yang, Rui
Slavin, Daniela
Der-Torossian, Hirak https://orcid.org/0000-0002-9902-5712
Chin, Curtis D.
Tannir, Nizar M.
Wang, Linghua https://orcid.org/0000-0001-9380-0266
Gao, Jianjun https://orcid.org/0000-0001-6138-4472
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA288448)
U.S. Department of Defense (KC200096P1)
- License Information
-
More Information
Article History
Received: 20 August 2024
Accepted: 19 December 2024
First Online: 10 January 2025
Competing interests
: P. Msaouel has received honoraria for service on a Scientific Advisory Board for Mirati Therapeutics, Bristol Myers Squibb, and Exelixis; consulting for Axiom Healthcare Strategies and DAVA Oncology; non-branded educational programs supported by Exelixis and Pfizer; and research funding for clinical trials from Takeda, Bristol Myers Squibb, Mirati Therapeutics, Gateway for Cancer Research, and the University of Texas MD Anderson Cancer Center. J. Gao serves as a consultant for AstraZeneca, Aveo Pharmaceuticals, CRISPR Therapeutics, Infinity Pharmaceuticals, Janssen, Jounce, Pfizer, Polaris, and Symphogen. N. M. Tannir reported receiving and personal fees (honoraria) from Calithera Biosciences during the conduct of the study; and grants (sponsored trial) from Calithera Biosciences, Bristol Myers Squibb (BMS), Nektar Therapeutics, Arrowhead Pharmaceuticals, and Novartis, as well as personal fees (honoraria) from Calithera Biosciences, BMS, Eisai Medical Research, Merck Sharp & Dohme (MSD), Deka Biosciences, Neoleukin Therapeutics, Exelixis, and Ono Pharmaceutical outside the submitted work. A.J. Zurita has served as an advisor for AstraZeneca, Bayer, Exelixis, Foundation Medicine, and Pfizer; reports payments for speaking or manuscript support from Amedco, CancerNet, Hikma, Janssen-Cilag, Mckesson Specialty Health, and Pfizer; and declares grants or contracts from Merck, Pfizer, Astellas, ABX, Clarity, and Curium outside the submitted work. M. Hallin, P. Olson, R.Yang, D. Slavin, H. Der-Torossian, and C. D. Chin are employees of Mirati Therapeutics, Inc. The remaining authors declare no competing interests.
